An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

计划入组 161 人 · 首次发布于 2015 年 7 月 15 日

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

计划入组 360 人 · 首次发布于 2025 年 7 月 15 日

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

计划入组 360 人 · 首次发布于 2025 年 9 月 9 日

mesenchymal stem cell therapy (respiratory distress syndrome)

Acute Respiratory Distress Syndrome therapy(ImStem Biotechnology, Inc)

immunological directed cellular therapy (oral, acute respiratory distress syndrome)

Edesa Biotech

Canada

Combat Stress

United Kingdom

Antios Therapeutics, Inc.

United States

Seaport Therapeutics Initiates Phase 2b Trial of Novel Oral Antidepressant GlyphAllo

Three Novel Anxiety Medications Advance Toward 2026 FDA Review, Marking First Major Breakthrough in Over a Decade

Seaport Therapeutics reports positive Phase 1 topline results from driving simulation study